LSL:CA:TSV-LSL Pharma Group Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.48

Change

+0.01 (+2.13)%

Market Cap

USD 0.05B

Volume

2.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical and natural health products in Canada. It offers dietary supplements and vitamins in the tablet and capsule form; and niche sterile ophthalmic products in the form of ointments and drops for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.30 (+2.80%)

USD 0.12B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.07B
SBBC:CA Simply Better Brands Corp

-0.01 (-1.67%)

USD 0.06B
LOVE:CA Cannara Biotech Inc

N/A

USD 0.06B
DB:CA Decibel Cannabis Company Inc

-0.01 (-6.67%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

N/A

USD 0.03B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.02B
MPH:CA Medicure Inc

N/A

USD 0.01B
CANB:CA CanadaBis Capital Inc

N/A

USD 7.60M
VM:CA Voyageur Pharmaceuticals Ltd

-0.01 (-9.09%)

USD 6.28M

ETFs Containing LSL:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.03% 63% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.03% 63% D 57% F
Trailing 12 Months  
Capital Gain 9.09% 87% B+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.09% 87% B+ 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.67% 50% F 43% F
Dividend Return -4.67% 50% F 43% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.82% 94% A 98% N/A
Risk Adjusted Return -33.76% 38% F 31% F
Market Capitalization 0.05B 75% C 84% B

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector